Cargando…
Drug repurposing for Dravet syndrome in scn1Lab (−/−) mutant zebrafish
Dravet syndrome (DS) is a severe genetic epileptic encephalopathy with onset during the first year of life. Zebrafish models recapitulating human diseases are often used as drug discovery platforms, but also for drug repurposing testing. It was recently shown that pharmacological modulation of three...
Autores principales: | Sourbron, Jo, Partoens, Michèle, Scheldeman, Chloë, Zhang, Yifan, Lagae, Lieven, de Witte, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850687/ https://www.ncbi.nlm.nih.gov/pubmed/30663052 http://dx.doi.org/10.1111/epi.14647 |
Ejemplares similares
-
Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
por: Sourbron, Jo, et al.
Publicado: (2017) -
Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
por: Li, Jing, et al.
Publicado: (2021) -
Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome
por: Grone, Brian P., et al.
Publicado: (2017) -
Serotonergic modulation as a pharmacological modality in the treatment of Dravet syndrome
por: de Witte, Peter, et al.
Publicado: (2017) -
Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet Syndrome treatment
por: Baraban, Scott C., et al.
Publicado: (2013)